{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:26:40Z","timestamp":1792114000821,"version":"4.4.0"},"reference-count":94,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protein acetylation is an important contributor to cancer initiation. Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability and has been implicated in JAK2-driven diseases best exemplified by myeloproliferative neoplasms (MPNs). By using novel classes of highly selective HDAC inhibitors and genetically deficient mouse models, we discovered that HDAC11 rather than HDAC6 is necessary for the proliferation and survival of oncogenic JAK2-driven MPN cells and patient samples. Notably, HDAC11 is variably expressed in primitive stem cells and is expressed largely upon lineage commitment. Although Hdac11is dispensable for normal homeostatic hematopoietic stem and progenitor cell differentiation based on chimeric bone marrow reconstitution, Hdac11 deficiency significantly reduced the abnormal megakaryocyte population, improved splenic architecture, reduced fibrosis, and increased survival in the MPLW515L-MPN mouse model during primary and secondary transplantation. Therefore, inhibitors of HDAC11 are an attractive therapy for treating patients with MPN. Although JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis. This study establishes HDAC11 as a unique type of target molecule that has therapeutic potential in MPN.<\/jats:p>","DOI":"10.1182\/blood.2019895326","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T15:48:20Z","timestamp":1574351300000},"page":"191-207","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":58,"title":["HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8578-7564","authenticated-orcid":false,"given":"Lanzhu","family":"Yue","sequence":"first","affiliation":[{"name":"Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China;"},{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-7696","authenticated-orcid":false,"given":"Vasundhara","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Horvat","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afua A.","family":"Akuffo","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"},{"name":"Cancer Biology PhD Program, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Beatty","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-8194","authenticated-orcid":false,"given":"Cem","family":"Murdun","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"},{"name":"Tissue Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Colin","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2831-1428","authenticated-orcid":false,"given":"Julia M. R.","family":"Billington","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"},{"name":"Cancer Biology PhD Program, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Goodheart","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-2275","authenticated-orcid":false,"given":"Eva","family":"Sahakian","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of South Florida College of Medicine and Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-2645","authenticated-orcid":false,"given":"John J.","family":"Powers","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-5907","authenticated-orcid":false,"given":"Narmin E.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Que T.","family":"Lambert-Showers","sequence":"additional","affiliation":[{"name":"Tissue Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lancia N.","family":"Darville","sequence":"additional","affiliation":[{"name":"Proteomics Core, Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-931X","authenticated-orcid":false,"given":"Gary W.","family":"Reuther","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2951-5748","authenticated-orcid":false,"given":"Kenneth L.","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Conti","sequence":"additional","affiliation":[{"name":"Forma Therapeutics, Watertown, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Forma Therapeutics, Watertown, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Forma Therapeutics, Watertown, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Yee","family":"Ng","sequence":"additional","affiliation":[{"name":"Forma Therapeutics, Watertown, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-2209","authenticated-orcid":false,"given":"Matthew W.","family":"Martin","sequence":"additional","affiliation":[{"name":"Forma Therapeutics, Watertown, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Gary","family":"Marshall","sequence":"additional","affiliation":[{"name":"Forma Therapeutics, Watertown, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-1762","authenticated-orcid":false,"given":"John M.","family":"Koomen","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Leukemia Center, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-7693","authenticated-orcid":false,"given":"Amit","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Hemato-Oncology, Department of Oncology, Albert Einstein College of Medicine, Bronx, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-6758","authenticated-orcid":false,"given":"H. Leighton","family":"Grimes","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology and Division of Pathology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M.","family":"Sotomayor","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, George Washington Cancer Center, Washington, DC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-8784","authenticated-orcid":false,"given":"Pearlie K.","family":"Epling-Burnette","sequence":"additional","affiliation":[{"name":"Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;"},{"name":"James A. Haley VA Hospital, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2020011611594253200_B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"2020011611594253200_B2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/asheducation-2014.1.277","article-title":"Therapy for myeloproliferative neoplasms: when, which agent, and how?","volume":"2014","author":"Geyer","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"23","key":"2020011611594253200_B3","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020011611594253200_B4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","article-title":"Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients","volume":"160","author":"Bonicelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"2020011611594253200_B5","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"17","key":"2020011611594253200_B6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"2020011611594253200_B7","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"25","key":"2020011611594253200_B8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"2020011611594253200_B9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"2020011611594253200_B10","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2020011611594253200_B11","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2020011611594253200_B12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12185-013-1353-5","article-title":"Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms","volume":"97","author":"Bhagwat","year":"2013","journal-title":"Int J Hematol"},{"issue":"8","key":"2020011611594253200_B13","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020011611594253200_B14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.24259","article-title":"LNK mutations and myeloproliferative disorders","volume":"91","author":"McMullin","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2020011611594253200_B15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.18632\/oncotarget.281","article-title":"Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies","volume":"2","author":"Passamonti","year":"2011","journal-title":"Oncotarget"},{"issue":"10","key":"2020011611594253200_B16","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3109\/10428194.2015.1037762","article-title":"Novel therapies for myelofibrosis","volume":"56","author":"Stein","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020011611594253200_B17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PPO.0000000000000169","article-title":"Treatment of myelofibrosis: A moving target","volume":"22","author":"Cerquozzi","year":"2016","journal-title":"Cancer J"},{"issue":"6","key":"2020011611594253200_B18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch Pharm Res"},{"issue":"4","key":"2020011611594253200_B19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"24","key":"2020011611594253200_B20","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1182\/blood-2009-05-222133","article-title":"Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2020011611594253200_B21","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.1158\/1078-0432.CCR-13-0905","article-title":"JAK1\/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease","volume":"19","author":"Evrot","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020011611594253200_B22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.12384","article-title":"Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis","volume":"162","author":"DeAngelo","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2020011611594253200_B23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjh.12220","article-title":"A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera\/essential thrombocythaemia myelofibrosis (post-PV\/ET MF)","volume":"161","author":"Mascarenhas","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2020011611594253200_B24","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"2020011611594253200_B25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/asheducation-2013.1.545","article-title":"Beyond JAK inhibitor therapy in myelofibrosis","volume":"2013","author":"Odenike","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"29","key":"2020011611594253200_B26","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"key":"2020011611594253200_B27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/B978-0-12-397927-8.00015-4","article-title":"HSP90 inhibitors for cancer therapy and overcoming drug resistance","volume":"65","author":"Jhaveri","year":"2012","journal-title":"Adv Pharmacol"},{"issue":"28","key":"2020011611594253200_B28","doi-asserted-by":"crossref","first-page":"25748","DOI":"10.1074\/jbc.M111871200","article-title":"Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family","volume":"277","author":"Gao","year":"2002","journal-title":"J Biol Chem"},{"key":"2020011611594253200_B29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ebiom.2018.06.025","article-title":"Programming and regulation of metabolic homeostasis by HDAC11","volume":"33","author":"Sun","year":"2018","journal-title":"EBioMedicine"},{"issue":"2","key":"2020011611594253200_B30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1189\/jlb.1A0415-176RRR","article-title":"Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology","volume":"102","author":"Sahakian","year":"2017","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2020011611594253200_B31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.molimm.2014.08.002","article-title":"Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function","volume":"63","author":"Sahakian","year":"2015","journal-title":"Mol Immunol"},{"issue":"7","key":"2020011611594253200_B32","doi-asserted-by":"crossref","first-page":"e90932","DOI":"10.1172\/jci.insight.90932","article-title":"Efficacy of ALK5 inhibition in myelofibrosis","volume":"2","author":"Yue","year":"2017","journal-title":"JCI Insight"},{"issue":"5","key":"2020011611594253200_B33","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cell.2017.04.018","article-title":"Vitamin A-retinoic acid signaling regulates hematopoietic stem cell dormancy","volume":"169","author":"Cabezas-Wallscheid","year":"2017","journal-title":"Cell"},{"issue":"4","key":"2020011611594253200_B34","doi-asserted-by":"crossref","first-page":"e1006913","DOI":"10.1371\/journal.pcbi.1006913","article-title":"Clonal hematopoiesis of indeterminate potential and its impact on patient trajectories after stem cell transplantation","volume":"15","author":"Park","year":"2019","journal-title":"PLOS Comput Biol"},{"issue":"3","key":"2020011611594253200_B35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40778-015-0019-z","article-title":"Transcriptional control of stem and progenitor potential","volume":"1","author":"Muench","year":"2015","journal-title":"Curr Stem Cell Rep"},{"issue":"37","key":"2020011611594253200_B36","doi-asserted-by":"crossref","first-page":"40141","DOI":"10.18632\/oncotarget.5653","article-title":"The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells","volume":"6","author":"Mazzacurati","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"2020011611594253200_B37","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"issue":"4","key":"2020011611594253200_B38","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2020011611594253200_B39","article-title":"inventors; FORMA Therapeutics Inc, assignee. 3-Alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors","volume-title":"International application WO\/2016\/126725","author":"Zheng"},{"issue":"3","key":"2020011611594253200_B40","doi-asserted-by":"crossref","first-page":"BSR20181916","DOI":"10.1042\/BSR20181916","article-title":"The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma","volume":"39","author":"Sun","year":"2019","journal-title":"Biosci Rep"},{"issue":"9","key":"2020011611594253200_B41","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nchembio.2140","article-title":"Structural insights into HDAC6 tubulin deacetylation and its selective inhibition","volume":"12","author":"Miyake","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"5","key":"2020011611594253200_B42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/emboj\/cdg115","article-title":"HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo","volume":"22","author":"Zhang","year":"2003","journal-title":"EMBO J"},{"issue":"6887","key":"2020011611594253200_B43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"issue":"12","key":"2020011611594253200_B44","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bmcl.2018.05.021","article-title":"Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11","volume":"28","author":"Martin","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"2020011611594253200_B45","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1021\/pr101065j","article-title":"Andromeda: a peptide search engine integrated into the MaxQuant environment","volume":"10","author":"Cox","year":"2011","journal-title":"J Proteome Res"},{"issue":"7","key":"2020011611594253200_B46","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open source document editor for creating and analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"},{"issue":"10","key":"2020011611594253200_B47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6-HSP90 interplay in malignant cells","volume":"35","author":"Kr\u00e4mer","year":"2014","journal-title":"Trends Pharmacol Sci"},{"issue":"5942","key":"2020011611594253200_B48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"key":"2020011611594253200_B49","author":"Ng","year":"2016"},{"key":"2020011611594253200_B50","author":"Lee","year":"2018"},{"issue":"1","key":"2020011611594253200_B51","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428194.2011.597905","article-title":"Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms","volume":"53","author":"Skov","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2020011611594253200_B52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.cdd.4400213","article-title":"Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death","volume":"4","author":"McGahon","year":"1997","journal-title":"Cell Death Differ"},{"issue":"1","key":"2020011611594253200_B53","doi-asserted-by":"crossref","first-page":"e0166014","DOI":"10.1371\/journal.pone.0166014","article-title":"Mesenchymal cell reprogramming in experimental MPLW515L mouse model of myelofibrosis","volume":"12","author":"Han","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"2020011611594253200_B54","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Arana Yi","year":"2015","journal-title":"Future Oncol"},{"issue":"7031","key":"2020011611594253200_B55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature03441","article-title":"Systematic discovery of regulatory motifs in human promoters and 3\u2032 UTRs by comparison of several mammals","volume":"434","author":"Xie","year":"2005","journal-title":"Nature"},{"issue":"6","key":"2020011611594253200_B56","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"12","key":"2020011611594253200_B57","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/35104049","article-title":"BAC to the future: the use of bac transgenic mice for neuroscience research","volume":"2","author":"Heintz","year":"2001","journal-title":"Nat Rev Neurosci"},{"issue":"7622","key":"2020011611594253200_B58","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nature19348","article-title":"Single-cell analysis of mixed-lineage states leading to a binary cell fate choice","volume":"537","author":"Olsson","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2020011611594253200_B59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"2020011611594253200_B60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2020011611594253200_B61","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"2020011611594253200_B62","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020011611594253200_B63","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/leu.2014.306","article-title":"Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis","volume":"29","author":"Pardanani","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"2020011611594253200_B64","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jnci\/djp216","article-title":"JAK2 inhibitors: not the next imatinib but researchers see other possibilities","volume":"101","author":"Garber","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2020011611594253200_B65","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"9","key":"2020011611594253200_B66","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","article-title":"Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis","volume":"36","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Leuk Res"},{"issue":"1","key":"2020011611594253200_B67","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2013.096669","article-title":"A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis","volume":"99","author":"Andersen","year":"2014","journal-title":"Haematologica"},{"issue":"19","key":"2020011611594253200_B68","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020011611594253200_B69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/10428194.2014.916805","article-title":"Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts","volume":"56","author":"Tabarroki","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020011611594253200_B70","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"2020011611594253200_B71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"Kovacs","year":"2005","journal-title":"Mol Cell"},{"issue":"12","key":"2020011611594253200_B72","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0960-9822(00)00542-X","article-title":"Active maintenance of mHDA2\/mHDAC6 histone-deacetylase in the cytoplasm","volume":"10","author":"Verdel","year":"2000","journal-title":"Curr Biol"},{"issue":"24","key":"2020011611594253200_B73","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1093\/emboj\/cdf682","article-title":"In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation","volume":"21","author":"Matsuyama","year":"2002","journal-title":"EMBO J"},{"issue":"40","key":"2020011611594253200_B74","doi-asserted-by":"crossref","first-page":"33792","DOI":"10.1074\/jbc.M506997200","article-title":"Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation\/deacetylation of the chaperone","volume":"280","author":"Murphy","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"2020011611594253200_B75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.molcel.2006.12.008","article-title":"An acetylation site in the middle domain of Hsp90 regulates chaperone function","volume":"25","author":"Scroggins","year":"2007","journal-title":"Mol Cell"},{"issue":"37","key":"2020011611594253200_B76","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/sj.onc.1210614","article-title":"HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination","volume":"26","author":"Boyault","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"2020011611594253200_B77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nbt.3130","article-title":"Acetylation site specificities of lysine deacetylase inhibitors in human cells","volume":"33","author":"Sch\u00f6lz","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2020011611594253200_B78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2017.01.033","article-title":"HDAC6 deacetylates p53 at lysines 381\/382 and differentially coordinates p53-induced apoptosis","volume":"391","author":"Ryu","year":"2017","journal-title":"Cancer Lett"},{"issue":"8","key":"2020011611594253200_B79","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1593\/neo.11558","article-title":"HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma","volume":"13","author":"Subramanian","year":"2011","journal-title":"Neoplasia"},{"issue":"4","key":"2020011611594253200_B80","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.celrep.2012.09.016","article-title":"Regulation of CD133 by HDAC6 promotes \u03b2-catenin signaling to suppress cancer cell differentiation","volume":"2","author":"Mak","year":"2012","journal-title":"Cell Reports"},{"issue":"1","key":"2020011611594253200_B81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ni.1673","article-title":"The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance","volume":"10","author":"Villagra","year":"2009","journal-title":"Nat Immunol"},{"issue":"15","key":"2020011611594253200_B82","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2018-09-876615","article-title":"Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis","volume":"133","author":"Wakahashi","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020011611594253200_B83","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/blood-2016-08-731505","article-title":"T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model","volume":"130","author":"Woods","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020011611594253200_B84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbagrm.2017.12.002","article-title":"HDAC11 is a regulator of diverse immune functions","volume":"1861","author":"Yanginlar","year":"2018","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"2020011611594253200_B85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ebiom.2018.08.008","article-title":"Histone deacetylase 11 as a key regulator of metabolism and obesity","volume":"35","author":"Bhaskara","year":"2018","journal-title":"EBioMedicine"},{"issue":"9","key":"2020011611594253200_B86","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/ijc.27876","article-title":"HDAC11 is a novel drug target in carcinomas","volume":"132","author":"Deubzer","year":"2013","journal-title":"Int J Cancer"},{"issue":"10","key":"2020011611594253200_B87","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2010-08-303701","article-title":"HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma","volume":"117","author":"Buglio","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2020011611594253200_B88","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/acschembio.7b00942","article-title":"Histone deacetylase 11 is a fatty-acid deacylase","volume":"13","author":"Kutil","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"3","key":"2020011611594253200_B89","doi-asserted-by":"crossref","first-page":"e2635","DOI":"10.1038\/cddis.2017.49","article-title":"Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival","volume":"8","author":"Thole","year":"2017","journal-title":"Cell Death Dis"},{"issue":"1","key":"2020011611594253200_B90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CCO.0b013e32835b639e","article-title":"p21WAF1 and tumourigenesis: 20 years after","volume":"25","author":"Warfel","year":"2013","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"2020011611594253200_B91","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1186\/s12885-016-2807-y","article-title":"The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways","volume":"16","author":"Hrgovic","year":"2016","journal-title":"BMC Cancer"},{"issue":"3","key":"2020011611594253200_B92","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"7-8","key":"2020011611594253200_B93","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.biocel.2007.03.001","article-title":"Histone deacetylase inhibitors: signalling towards p21cip1\/waf1","volume":"39","author":"Ocker","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"2020011611594253200_B94","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1756-8722-7-25","article-title":"Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice","volume":"7","author":"Shi","year":"2014","journal-title":"J Hematol Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/3\/191\/1552422\/blood895326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/3\/191\/1552422\/blood895326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T14:13:36Z","timestamp":1722089616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/3\/191\/428860\/HDAC11-deficiency-disrupts-oncogeneinduced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":94,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019895326","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,16]]}}}